Simulations Plus (NASDAQ:SLP) CRO John Anthony Dibella II Sells 1,000 Shares of Stock

Simulations Plus, Inc. (NASDAQ:SLP) CRO John Anthony Dibella II sold 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $13.37, for a total transaction of $13,370.00. Following the sale, the executive directly owned 89,140 shares in the company, valued at approximately $1,191,801.80. The trade was a 1.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Simulations Plus Stock Down 3.6%

Shares of SLP stock opened at $14.12 on Friday. The firm has a 50 day moving average of $12.36 and a two-hundred day moving average of $15.93. The stock has a market capitalization of $285.22 million, a PE ratio of -4.51 and a beta of 1.19. Simulations Plus, Inc. has a 52 week low of $11.09 and a 52 week high of $36.45.

Simulations Plus (NASDAQ:SLP) last announced its quarterly earnings data on Thursday, April 9th. The technology company reported $0.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.08. The business had revenue of $24.29 million for the quarter, compared to analysts’ expectations of $21.66 million. Simulations Plus had a positive return on equity of 16.21% and a negative net margin of 77.96%. Analysts expect that Simulations Plus, Inc. will post 1.09 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have commented on SLP. Wall Street Zen cut shares of Simulations Plus from a “buy” rating to a “hold” rating in a report on Saturday, April 4th. BTIG Research lowered shares of Simulations Plus from a “buy” rating to a “neutral” rating in a report on Thursday, December 18th. Zacks Research downgraded shares of Simulations Plus from a “strong-buy” rating to a “hold” rating in a research note on Monday, February 2nd. TD Cowen dropped their target price on Simulations Plus from $19.00 to $16.00 and set a “hold” rating on the stock in a report on Friday, April 10th. Finally, Citigroup restated a “market perform” rating on shares of Simulations Plus in a research note on Tuesday, January 6th. Three analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $24.40.

Institutional Trading of Simulations Plus

Large investors have recently bought and sold shares of the business. Raymond James Financial Inc. acquired a new position in Simulations Plus in the second quarter valued at $25,000. Quarry LP acquired a new stake in shares of Simulations Plus during the third quarter worth about $28,000. CWM LLC boosted its stake in shares of Simulations Plus by 3,729.1% during the third quarter. CWM LLC now owns 2,106 shares of the technology company’s stock worth $32,000 after buying an additional 2,051 shares during the period. Farther Finance Advisors LLC purchased a new position in shares of Simulations Plus during the third quarter worth about $40,000. Finally, Caitong International Asset Management Co. Ltd increased its position in Simulations Plus by 343.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,983 shares of the technology company’s stock valued at $73,000 after acquiring an additional 3,084 shares during the period. Institutional investors and hedge funds own 78.08% of the company’s stock.

Simulations Plus Company Profile

Simulations Plus, Inc (NASDAQ: SLP) specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company’s flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics.